Search Results

There are 100639 results for: content related to: Comparison of long-term clinical outcome with etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity

  1. You have free access to this content
    2015 ACR/ARHP Annual Meeting Abstract Supplement

    Arthritis & Rheumatology

    Volume 67, Issue S10, October 2015, Pages: 1–4046,

    Version of Record online : 5 NOV 2015, DOI: 10.1002/art.39448

  2. You have free access to this content
    ACR Meeting

    Arthritis & Rheumatism

    Volume 64, Issue S10, October 2012, Pages: S1–S1216,

    Version of Record online : 11 OCT 2012, DOI: 10.1002/art.37735

  3. Adalimumab for treating rheumatoid arthritis

    Intervention Review

    The Cochrane Library

    Federico Navarro-Sarabia, Rafael Ariza-Ariza, Blanca Hernandez-Cruz and Isidro Villanueva

    Published Online : 20 JUL 2005, DOI: 10.1002/14651858.CD005113.pub2

  4. Etanercept for patients with psoriasis who did not respond or who lost their response to adalimumab or infliximab

    Journal of the European Academy of Dermatology and Venereology

    Volume 29, Issue 8, August 2015, Pages: 1576–1581, R. Bissonnette, C. Maari, K. Barber, C.W. Lynde and R. Vender

    Version of Record online : 20 JAN 2015, DOI: 10.1111/jdv.12943

  5. You have full text access to this OnlineOpen article
    Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: Findings of a phase IIIb, multinational, prospective, randomized study

    Arthritis & Rheumatism

    Volume 65, Issue 1, January 2013, Pages: 28–38, Michael E. Weinblatt, Michael Schiff, Robert Valente, Désirée van der Heijde, Gustavo Citera, Cathy Zhao, Michael Maldonado and Roy Fleischmann

    Version of Record online : 27 DEC 2012, DOI: 10.1002/art.37711

  6. You have free access to this content
    TNF-alpha inhibitors for ankylosing spondylitis

    Intervention Review

    The Cochrane Library

    Lara J Maxwell, Jane Zochling, Annelies Boonen, Jasvinder A Singh, Mirella MS Veras, Elizabeth Tanjong Ghogomu, Maria Benkhalti Jandu, Peter Tugwell and George A Wells

    Published Online : 18 APR 2015, DOI: 10.1002/14651858.CD005468.pub2

  7. Efficacy, safety and medication cost implications of adalimumab 40 mg weekly dosing in patients with psoriasis with suboptimal response to 40 mg every other week dosing: results from an open-label study

    British Journal of Dermatology

    Volume 167, Issue 3, September 2012, Pages: 658–667, C. Leonardi, J.M. Sobell, J.J. Crowley, U. Mrowietz, Y. Bao, P.M. Mulani, Y. Gu and M.M. Okun

    Version of Record online : 20 AUG 2012, DOI: 10.1111/j.1365-2133.2012.11041.x

  8. You have free access to this content
    Adalimumab for long-term treatment of psoriatic arthritis: Forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial

    Arthritis & Rheumatism

    Volume 56, Issue 2, February 2007, Pages: 476–488, Dafna D. Gladman, Philip J. Mease, Christopher T. Ritchlin, Ernest H. S. Choy, John T. Sharp, Peter A. Ory, Renee J. Perdok and Eric H. Sasso

    Version of Record online : 30 JAN 2007, DOI: 10.1002/art.22379

  9. You have free access to this content
    Adalimumab dose escalation is effective for managing secondary loss of response in Crohn's disease

    Alimentary Pharmacology & Therapeutics

    Volume 40, Issue 9, November 2014, Pages: 1044–1055, C. Ma, V. Huang, D. K. Fedorak, K. I. Kroeker, L. A. Dieleman, B. P. Halloran and R. N. Fedorak

    Version of Record online : 3 SEP 2014, DOI: 10.1111/apt.12940

  10. Caspase activation and apoptosis induction by adalimumab: Demonstration in vitro and in vivo in a chimeric mouse model

    Inflammatory Bowel Diseases

    Volume 12, Issue 1, January 2006, Pages: 22–28, Chong Shen, Gert Van Assche, Paul Rutgeerts and Jan L Ceuppens

    Version of Record online : 14 DEC 2006, DOI: 10.1097/01.MIB.0000194185.69800.07

  11. Risk–benefit analysis of adalimumab versus traditional non-biologic therapies for patients with Crohn's disease

    Inflammatory Bowel Diseases

    Volume 17, Issue 1, January 2011, Pages: 127–140, Edward V. Loftus Jr, Scott J. Johnson, Si-Tien Wang, Eric Wu, Parvez M. Mulani and Jingdong Chao

    Version of Record online : 1 JUN 2010, DOI: 10.1002/ibd.21341

  12. Effect of adalimumab on clinical laboratory parameters in patients with Crohn's disease: Results from the CHARM trial

    Inflammatory Bowel Diseases

    Volume 18, Issue 5, May 2012, Pages: 818–825, David T. Rubin, Parvez Mulani, Jingdong Chao, Paul F. Pollack, Arielle G. Bensimon, Andrew P. Yu and Subrata Ghosh

    Version of Record online : 1 SEP 2011, DOI: 10.1002/ibd.21836

  13. The effectiveness and safety of adalimumab in the treatment of non-reimbursed patients with mild-to-moderate psoriasis

    Journal of the European Academy of Dermatology and Venereology

    Volume 26, Issue 8, August 2012, Pages: 991–998, H.-Y. Chiu, T.-S. Wang, C.-Y. Chang and T.-F. Tsai

    Version of Record online : 4 AUG 2011, DOI: 10.1111/j.1468-3083.2011.04199.x

  14. You have full text access to this OnlineOpen article
    A prospective, randomized, double-blind, multicentre, parallel-group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC-3197) and adalimumab (Humira) in patients with rheumatoid arthritis

    International Journal of Rheumatic Diseases

    Rajendrakumar H. Jani, Rajiv Gupta, Girish Bhatia, Gaurav Rathi, Patnala Ashok Kumar, Reena Sharma, Uma Kumar, Liyakat A. Gauri, Praveen Jadhav, Girishchandra Bartakke, Vikram Haridas, Dinesh Jain and Sanjeev K. Mendiratta

    Version of Record online : 14 JUL 2015, DOI: 10.1111/1756-185X.12711

  15. You have free access to this content
    Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn’s disease

    Alimentary Pharmacology & Therapeutics

    Volume 31, Issue 12, June 2010, Pages: 1296–1309, R. PANACCIONE, J.-F. COLOMBEL, W. J. SANDBORN, P. RUTGEERTS, G. R. D’HAENS, A. M. ROBINSON, J. CHAO, P. M. MULANI and P. F. POLLACK

    Version of Record online : 18 MAR 2010, DOI: 10.1111/j.1365-2036.2010.04304.x

  16. You have free access to this content
    Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: Efficacy and safety results from a Phase II/III randomized controlled study

    The Journal of Dermatology

    Volume 37, Issue 4, April 2010, Pages: 299–310, Akihiko ASAHINA, Hidemi NAKAGAWA, Takafumi ETOH, Mamitaro OHTSUKI and THE ADALIMUMAB M04-688 STUDY GROUP

    Version of Record online : 26 FEB 2010, DOI: 10.1111/j.1346-8138.2009.00748.x

  17. You have free access to this content
    Pharmacokinetics and concentration–effect relationship of adalimumab in rheumatoid arthritis

    British Journal of Clinical Pharmacology

    Volume 79, Issue 2, February 2015, Pages: 286–297, David Ternant, Emilie Ducourau, Piéra Fuzibet, Céline Vignault, Hervé Watier, Thierry Lequerré, Xavier Le Loët, Olivier Vittecoq, Philippe Goupille, Denis Mulleman and Gilles Paintaud

    Version of Record online : 20 JAN 2015, DOI: 10.1111/bcp.12509

  18. Abstracts from the 2008 Advances in Inflammatory Bowel Diseases, Crohn's & Colitis Foundation's National Clinical & Research Conference

    Inflammatory Bowel Diseases

    Volume 14, Issue S3, December 2008, Pages: S1–S49,

    Version of Record online : 26 NOV 2008, DOI: 10.1002/ibd.20829

  19. You have full text access to this OnlineOpen article
    A Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Adalimumab in Pediatric Patients With Enthesitis-Related Arthritis

    Arthritis Care & Research

    Volume 67, Issue 11, November 2015, Pages: 1503–1512, Rubén Burgos-Vargas, Shirley M. L. Tse, Gerd Horneff, Aileen L. Pangan, Jasmina Kalabic, Sandra Goss, Kristina Unnebrink and Jaclyn K. Anderson

    Version of Record online : 27 OCT 2015, DOI: 10.1002/acr.22657

  20. Biologics for rheumatoid arthritis: an overview of Cochrane reviews

    Overview of Reviews

    The Cochrane Library

    Jasvinder A Singh, Robin Christensen, George A Wells, Maria E Suarez-Almazor, Rachelle Buchbinder, Maria Angeles Lopez-Olivo, Elizabeth Tanjong Ghogomu and Peter Tugwell

    Published Online : 7 OCT 2009, DOI: 10.1002/14651858.CD007848.pub2